VANCOUVER, BC--(MARKET WIRE)--Jun 14, 2006 -- Upstream Biosciences Inc. (OTC BB:UPBS.OB - News) (“Upstream” or “the Company”), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the appointment of Dr. Robert D. Sindelar to its scientific advisory board. Dr. Sindelar is Professor and Dean of the Faculty of Pharmaceutical Sciences at The University of British Columbia.
